Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ASCO Annual Meeting 2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

2024 ASCO Annual Meeting

Keep up to date with all the top stories and latest evidence with our hub page, including official congress videos and expert takeaways.
ADVANCED SEARCH
Log in
Top
International Journal of Diabetes in Developing Countries
Published in: International Journal of Diabetes in Developing Countries 4/2022

12-11-2021 | Insulins | Original Article

Selenoprotein P levels in patients with diabetes mellitus with complications

Authors: Bilal Ilanbey, Hasan Esat Yücel, Cahit Uçar, Özkan Kocamış

Published in: International Journal of Diabetes in Developing Countries | Issue 4/2022

Login to get access

Abstract

Aims

Increasing evidence has shown that selenoprotein P levels are elevated in type 2 diabetes mellitus and are associated with insulin resistance and release. This study aimed to determine if there was a connection between selenoprotein P levels and metabolic parameters in patients with diabetes with microvascular complications.

Methods

Serum selenoprotein P concentrations were measured by ELISA in 44 patients with diabetes with complications and 36 patients with diabetes without complications.

Results

There was no statistically significant difference in selenoprotein P levels between the groups [1.9 (0.9–2.6) and 1.9 (0.8–2.4) ng/mL, respectively, p = 0.565]. Selenoprotein P, glucose, glycosylated hemoglobin, C-reactive protein, triglycerides, total cholesterol, and low-density lipoprotein cholesterol levels were not statistically significantly correlated in patients with complications. However, there was a significant correlation with high-density lipoprotein cholesterol (r = − 0.401, p = 0.042).

Conclusions

We did not find high selenoprotein P levels in patients with complications, but its inverse association with high-density lipoprotein cholesterol indicates that it may play a role in developing cardiovascular disease in this community of patients.
Literature
1.
2.
Litwak L, Goh S-Y, Hussein Z, Malek R, Prusty V, Khamseh ME. Prevalence of diabetes complications in people with type 2 diabetes mellitus and its association with baseline characteristics in the multinational a 1 chieve study. Diabetology & metabolic syndrome. 2013;5:1–10.CrossRef
3.
Association AD. 6. Glycemic targets: standards of medical care in diabetes—2021. Diabetes Care. 2021;44:S73–84.CrossRef
4.
Cosentino F, Grant PJ, Aboyans V, Bailey CJ, Ceriello A, Delgado V, et al. 2019 ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the task force for diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and the European Association for the Study of diabetes (EASD). Eur Heart J. 2019;41:255–323.CrossRef
5.
Stefan N, Haring HU. The role of hepatokines in metabolism. Nat Rev Endocrinol. 2013;9:144–52.CrossRef
6.
Brodin O, Hackler J, Misra S, Wendt S, Sun Q, Laaf E, et al. Selenoprotein P as biomarker of selenium status in clinical trials with therapeutic dosages of selenite. Nutrients. 2020;12:1067.CrossRef
7.
Hill KE, Wu S, Motley AK, Stevenson TD, Winfrey VP, Capecchi MR, et al. Production of selenoprotein P (Sepp1) by hepatocytes is central to selenium homeostasis. J Biol Chem. 2012;287:40414–24.CrossRef
8.
Misu H, Takamura T, Takayama H, Hayashi H, Matsuzawa-Nagata N, Kurita S, et al. A liver-derived secretory protein, selenoprotein P, causes insulin resistance. Cell Metab. 2010;12:483–95.CrossRef
9.
Mita Y, Nakayama K, Inari S, Nishito Y, Yoshioka Y, Sakai N, et al. Selenoprotein P-neutralizing antibodies improve insulin secretion and glucose sensitivity in type 2 diabetes mouse models. Nat Commun. 2017;8:1–17.CrossRef
10.
Oo SM, Misu H, Saito Y, Tanaka M, Kato S, Kita Y, et al. Serum selenoprotein P, but not selenium, predicts future hyperglycemia in a general Japanese population. Sci Rep. 2018;8:1–10.CrossRef
11.
Yang SJ, Hwang SY, Choi HY, Yoo HJ, Seo JA, Kim SG, et al. Serum selenoprotein P levels in patients with type 2 diabetes and prediabetes: implications for insulin resistance, inflammation, and atherosclerosis. J Clin Endocrinol Metab. 2011;96:E1325–9.CrossRef
12.
Ali SA, Nassif WM, Abdelaziz DH. Alterations in serum levels of fetuin a and selenoprotein P in chronic hepatitis C patients with concomitant type 2 diabetes: a case-control study. Clinics and research in hepatology and gastroenterology. 2016;40:465–70.CrossRef
13.
Zhang Q, Li W, Wang J, Hu B, Yun H, Guo R, et al. Selenium levels in community dwellers with type 2 diabetes mellitus. Biol Trace Elem Res. 2019;191:354–62.CrossRef
14.
Altinova AE, Iyidir OT, Ozkan C, Ors D, Ozturk M, Gulbahar O, et al. Selenoprotein P is not elevated in gestational diabetes mellitus. Gynecol Endocrinol. 2015;31:874–6.CrossRef
15.
Roman M, Lapolla A, Jitaru P, Sechi A, Cosma C, Cozzi G, et al. Plasma selenoproteins concentrations in type 2 diabetes mellitus—a pilot study. Transl Res. 2010;156:242–50.CrossRef
16.
Laiteerapong N, Ham SA, Gao Y, Moffet HH, Liu JY, Huang ES, et al. The legacy effect in type 2 diabetes: impact of early glycemic control on future complications (the Diabetes & Aging Study). Diabetes Care. 2019;42:416–26.CrossRef
17.
Femlak M, Gluba-Brzózka A, Ciałkowska-Rysz A, Rysz J. The role and function of HDL in patients with diabetes mellitus and the related cardiovascular risk. Lipids Health Dis. 2017;16:1–9.CrossRef
18.
Vergès B. Pathophysiology of diabetic dyslipidaemia: where are we? Diabetologia. 2015;58:886–99.CrossRef
19.
Schomburg L, Orho-Melander M, Struck J, Bergmann A, Melander O. Selenoprotein-p deficiency predicts cardiovascular disease and death. Nutrients. 2019;11:1852.CrossRef
20.
Speckmann B, Sies H, Steinbrenner H. Attenuation of hepatic expression and secretion of selenoprotein P by metformin. Biochem Biophys Res Commun. 2009;387:158–63.CrossRef
21.
Saito Y, Misu H, Takayama H, Takashima SI, Usui S, Takamura M, et al. Comparison of human selenoprotein P determinants in serum between our original methods and commercially available kits. Biol Pharm Bull. 2018;41:828–32.CrossRef
Metadata
Title
Selenoprotein P levels in patients with diabetes mellitus with complications
Authors
Bilal Ilanbey
Hasan Esat Yücel
Cahit Uçar
Özkan Kocamış
Publication date
12-11-2021
Publisher
Springer India
Published in
International Journal of Diabetes in Developing Countries / Issue 4/2022
Print ISSN: 0973-3930
Electronic ISSN: 1998-3832
DOI
https://doi.org/10.1007/s13410-021-01029-0

Other articles of this Issue 4/2022

International Journal of Diabetes in Developing Countries 4/2022 Go to the issue

Original Article

Total cholesterol and postprandial triglyceride levels as early markers of GDM in Asian Indian women

Letter to the Editor

Arterial systolic and diastolic blood pressure are not associated with HbA1c levels but arterial systolic blood pressure alone associated with 1-h postchallenge glucose levels

Original Article

Association between diabetes and acute lymphocytic leukemia, acute myeloid leukemia, non-Hopkin lymphoma, and multiple myeloma

Original Article

Correlation analysis of triglycerides to high-density lipoprotein-cholesterol ratio associated with gestational diabetes mellitus

Original Article

Comparison of biomarkers of oxidative stress, 8-isoprostane, advanced oxidation protein products, and 8-hydroxy-2′-deoxyguanosine and pro-apoptosis, cytokeratin 18 M30, in women with normal glucose tolerance and gestational diabetes mellitus

Original Article

Utility of urinary progranulin in patients with type 2 diabetic nephropathy and its correlation with renal function
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits